Any current/future new fundraising through debt or equity?

The company is investing heavily in growth projects including Bangalore, Nashik, and Thane hospitals. Capex for FY2024 is expected around Rs. 650-700 Crores (250 Crores for Bangalore & Nashik, 250 Crores approx. for Thane if asset-heavy). Discussions are ongoing with institutional investors for an asset-light model for the Thane project to reduce on-balance sheet Capex (~250 Crores reduction if successful). Current net debt is roughly Rs. 300 Crores, with a comfortable debt-to-EBITDA ratio guidance of 1.5 to 1.75 times. The company is generating strong cash flows (~Rs. 400 Crores annually) and

Any current/future capex/capital investment/strategic investment?

Ongoing Capex projects in Bangalore and Nashik, with approximately ₹250 Crores remaining, aiming for operationalization by Q1 FY2025 with initial 150 beds each. Capex of around ₹100 Crores planned for oncology bed additions, gas flow units, mother & child units, and relevant equipment at existing units. Thane hospital project (300 beds) with estimated total cost between ₹400-450 Crores; discussions ongoing for an asset-light model by involving institutional investors to reduce Capex on books by ₹250 Crores. Sunshine Hospital buyout involving Capex for building acquisition ongoing. Vizag hospit

Future growth expectations in sales/revenue/volumes?

KIMS aims to continue its growth trajectory with optimism, critically evaluating new opportunities for expansion and value addition. Existing Telangana and Andhra Pradesh mature assets have headroom for growth; Telangana Secunderabad is at 70% occupancy with room to grow over the next two years. Bed additions planned in FY2025 (e.g., Kondapur expansion) and FY2026 from mature Telangana and AP markets. New hospital facilities like Thane (300 beds) and Nashik (initial 150 operational beds out of capacity for 250-300 beds) expected to contribute to revenue growth. Gradual ramp-up of docto

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects to continue growth on the same trajectory with a positive and optimistic outlook. EBITDA margins are projected to improve, with some facilities expecting margin profile changes after new clinicians join. Incremental revenue growth is anticipated from hospital expansions and new doctor recruitments, e.g., a potential Rs. 7-8 Crores incremental revenue at Begumpet. Telangana assets expect high single-digit EBITDA growth, with new specialties and bed capacity expansions supporting this. Consolidated EBITDA margins improved recently, indicating operational efficiency gains. EPS

Current/ Expected Orderbook/ Pending Orders?

The transcript provided does not explicitly mention the current or expected order book or pending orders for KIMS Hospitals. The discussion mainly focuses on operational updates, expansions, bed capacity additions, margin improvements, and strategic plans. Key expansions include adding beds in Telangana (from 1200 to ~2000), Andhra Pradesh (from 645 to ~1200), new hospitals planned in Bangalore, Nashik, and Thane slated for FY2025. Nagpur and Sunshine hospital operational and margin progress discussed, but no explicit order book details. Capital expenditure plans mentioned: ₹250 Crores for Tha

Krishna Institute of Medical Sciences LtdQ4 FY23Healthcare Services

Krishna Institute of Medical Sciences Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹701.8P/E: 141.3Market Cap: ₹29.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

KIMS aims to continue its growth trajectory with optimism, critically evaluating new opportunities for expansion and value addition.
Existing Telangana and Andhra Pradesh mature assets have headroom for growth; Telangana Secunderabad is at 70% occupancy with room to grow over the next two years.
Bed additions planned in FY2025 (e.g., Kondapur expansion) and FY2026 from mature Telangana and AP markets.
New hospital facilities like Thane (300 beds) and Nashik (initial 150 operational beds out of capacity for 250-300 beds) expected to contribute to revenue growth.
Gradual ramp-up of doctor strength by 12-15 in next 6-9 months to increase patient flow and revenue.
Newly acquired Nagpur facility expected to improve EBITDA margin to 10-12% within 6-8 months.
Revenue growth driven by incremental clinician additions and phased hospital capacity activation.
Expansion focused on consolidating positions in current geographies before entering new ones.

Margin guidance

Category 3

The company expects to continue growth on the same trajectory with a positive and optimistic outlook.
EBITDA margins are projected to improve, with some facilities expecting margin profile changes after new clinicians join.
Incremental revenue growth is anticipated from hospital expansions and new doctor recruitments, e.g., a potential Rs. 7-8 Crores incremental revenue at Begumpet.
Telangana assets expect high single-digit EBITDA growth, with new specialties and bed capacity expansions supporting this.
Consolidated EBITDA margins improved recently, indicating operational efficiency gains.
EPS showed strong growth of 15.6% YoY and 22.8% QoQ in recent quarters.
Management expects stabilization periods of 6-9 months for new assets, with leadership recruitment as a priority for sustained growth.
Long-term ROIC targets around 25% margins and asset turnover of 1-1.25 times per bed.
Focus on organic growth from existing mature assets and strategic new acquisitions to drive future profit growth.

See what Krishna Institute of Medical Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is investing heavily in growth projects including Bangalore, Nashik, and Thane hospitals.
Capex for FY2024 is expected around Rs. 650-700 Crores (250 Crores for Bangalore & Nashik, 250 Crores approx. for Thane if asset-heavy).
Discussions are ongoing with institutional investors for an asset-light model for the Thane project to reduce on-balance sheet Capex (~250 Crores reduction if successful).
Current net debt is roughly Rs. 300 Crores, with a comfortable debt-to-EBITDA ratio guidance of 1.5 to 1.75 times.
The company is generating strong cash flows (~Rs. 400 Crores annually) and plans to deploy this cash for growth, with some possibility of front-loaded debt depending on project structures.
Overall, any additional debt or equity raise will depend on finalizing asset-light deals primarily for the Thane project. No explicit mention of new equity fundraising so far.

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders for KIMS Hospitals.
The discussion mainly focuses on operational updates, expansions, bed capacity additions, margin improvements, and strategic plans.
Key expansions include adding beds in Telangana (from 1200 to ~2000), Andhra Pradesh (from 645 to ~1200), new hospitals planned in Bangalore, Nashik, and Thane slated for FY2025.
Nagpur and Sunshine hospital operational and margin progress discussed, but no explicit order book details.
Capital expenditure plans mentioned: ₹250 Crores for Thane, ₹350 Crores ongoing for Nashik and Bangalore in FY2024.
No direct references to order book values or pending orders are made in the document excerpts provided.

See what Krishna Institute of Medical Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing Capex projects in Bangalore and Nashik, with approximately ₹250 Crores remaining, aiming for operationalization by Q1 FY2025 with initial 150 beds each.
Capex of around ₹100 Crores planned for oncology bed additions, gas flow units, mother & child units, and relevant equipment at existing units.
Thane hospital project (300 beds) with estimated total cost between ₹400-450 Crores; discussions ongoing for an asset-light model by involving institutional investors to reduce Capex on books by ₹250 Crores.
Sunshine Hospital buyout involving Capex for building acquisition ongoing.
Vizag hospital expansion (25 beds) operational in FY2024; Sunshine relocation with no new bed addition.
Focus on continuous growth with consolidation in current geographies before further expansion.
Capex expected to drive margin expansion and capacity growth over 3-6 years with ramp-up plans phased as occupancy improves.

Track Krishna Institute of Medical Sciences Ltd — get its next earnings analysis in your feed

How does Krishna Institute of Medical Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

ThisKrishna Institute of Medical Sciences Ltd

Rev 3Mar 3

See where Krishna Institute of Medical Sciences Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Krishna Institute of Medical Sciences Ltd rank in Healthcare Services?

Compare Krishna Institute of Medical Sciences Ltd against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Krishna Institute of Medical Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season

Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Krishna Institute of Medical Sciences Ltd Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Krishna Institute of Medical Sciences Ltd rank in Healthcare Services?

Continue your research

What Krishna Institute of Medical Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season